McMaster University

McMaster University

Jean-Claude Cutz

, MSc, MD, FRCPC

Associate Professor
Pathology and Molecular Medicine

Division: Anatomical Pathology

St. Joseph's Healthcare
L222-9, St. Luke's Wing
Hamilton, Ontario
905-522-1155 ext. 35005
jcutz@mcmaster.ca

Currently not accepting Graduate Students
Currently not accepting Post-Doctoral Fellows

Jean-Claude Cutz

Faculty Biography

Education and Professional Standing

CIHR, research Fellowship in Molecular Oncologic Pathology 2003-4
FRCPC, Anatomical Pathology 2002
MD, University of Toronto, 1997
MSc, Pharmacology, University of Toronto, 1993
BSc, Pharmacology, University of Toronto, 1991

Interests

Research Focus

  • Molecular mechanisms and diagnostic markers of neoplasia and carcinogenesis (lung, thyroid, prostate)
  • Application of newer molecular diagnostic and digital imaging techniques

Clinical Focus

  • Pulmonary Pathology (neoplastic and non-neoplastic conditions)
  • Head and neck pathology, especially thyroid
  • Pathologist consultant for the Anatomic Pathology Molecular Diagnostic Lab (FISH Lab)

Academic Interests

  • General surgical pathology
  • Teaching Undergraduate Medical Students
  • Teaching Residents subspecialties: pathology, pulmonary, head and neck, molecular
  • Resident Site Supervisor for St. Joseph’s Pathology

Mentorship of trainees interested in basic Molecular Pathology research, see http://www.molecularpathology.ca/

Dr. Cutz is the current secretary treasurer of the Hamilton Society of Pathologists, see http://www.pathologyhamilton.ca/; http://www.hhsc.ca/body.cfm?id=390

Dr. Cutz is the department representative for the Clinical Investigator Program (CIP), //fhs.mcmaster.ca/cip/


Team Members

Medical Laboratory Technician: Debbie Browning

Collaborations: Department of Medical and Radiation Oncology at JCC, Damu Tang Lab, St Joseph's Hospital

Selected Publications

  • Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz JC, Singh G, Wright J, Tsakiridis T. Ionizing Radiation Activates AMP-Activated Kinase (AMPK): A Target for Radiosensitization of Human Cancer Cells. Int J Radiat Oncol Biol Phys. 2010 Jul 7.
  • Fan C, He L, Kapoor A, Rybak AP, De Melo J, Cutz JC, Tang D. PTEN inhibits BMI1 function independently of its phosphatase activity. Mol Cancer. 2009 Nov 10;8:98.
  • Fan C, He L, Kapoor A, Gillis A, Rybak AP, Cutz JC, Tang D. Bmi1 promotes prostate tumorigenesis via inhibiting p16(INK4A) and p14(ARF) expression. Biochim Biophys Acta. 2008 Nov;1782(11):642-8.
  • Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008 Sep 10;26(26):4268-75.
  • Tsakiridis T, Cutz JC, Singh G, Hirte H, Okawara G, Corbett T, Sur R, Cai W, Whelan T, Wright JR. Association of phosphorylated epidermal growth factor receptor with survival in patients with locally advanced non-small cell lung cancer treated with radiotherapy. J Thorac Oncol. 2008 Jul;3(7):716-22.
  • Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008 Sep 10;26(26):4319-25.
  • Srigley JA, Cutz JC, Young JE, Morris AM. Fever of unknown origin in a migrant farm worker from Mexico: History, her story and his story. Can J Infect Dis Med Microbiol. 2007 Nov;18(6):368-9.
  • Al-Romaih K, Somers GR, Bayani J, Hughes S, Prasad M, Cutz JC, Xue H, Zielenska M, Wang Y, Squire JA. Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptotic genes as targets for demethylation.Cancer Cell Int. 2007 Sep 10;7:14.
  • Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Wang Y, Xue H, Karp CM, Cutz JC, Cunha GR, Wang YZ. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate. 2007 Feb 1;67(2):162-71.
  • Fan C, Quan R, Feng X, Gillis A, He L, Matsumoto ED, Salama S, Cutz JC, Kapoor A, Tang D. ATM activation is accompanied with earlier stages of prostate tumorigenesis. Biochim Biophys Acta. 2006 Oct;1763(10):1090-7.
  • Yoshimoto M, Cutz JC, Nuin PA, Joshua AM, Bayani J, Evans AJ, Zielenska M, Squire JA. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet. 2006 Sep;169(2):128-37.
  • Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire JA, Gout PW, Lam S, Wang YZ. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res. 2006 Jul 1;12(13):4043-54.
  • Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest. 2005 Nov;85(11):1392-404.
  • Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005 Jul 14;353(2):133-44. Erratum in: N Engl J Med. 2006 Oct 19;355(16):1746.

Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0